BostonPremier Wealth
CTXR icon

BostonPremier Wealth’s Citius Pharmaceuticals CTXR Stock Holding History

BostonPremier Wealth’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-28,000
Closed -$16.9K – 86
2026
Q2 		$16.9K Buy
+28,000
New +$19K 0.01% 79

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return
Asset Advisory Group
Asset Advisory Group Kinnelon, New Jersey $232M AUM 16.51% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Quent Capital
Quent Capital New York $1.67B AUM 19.79% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Princeton Global Asset Management
Princeton Global Asset Management Princeton, New Jersey $692M AUM 20.31% 1-Year Est. Return

BostonPremier Wealth's CTXR Position: Q3 2026 in Review

BostonPremier Wealth sold out of Citius Pharmaceuticals (CTXR) in Q3 2026, closing a stake of 28,000 shares — an estimated $16.9K sold.

BostonPremier Wealth first reported a position in CTXR in Q2 2026 and held it in 1 quarter. The position peaked at $16.9K in Q2 2026. 11 funds tracked by Wall St. Rank hold CTXR as of Q3 2026.

  • BostonPremier Wealth reported no remaining Citius Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • BostonPremier Wealth sold 28,000 Citius Pharmaceuticals shares in Q3 2026, an estimated $16.9K.
  • BostonPremier Wealth first reported a position in Citius Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • BostonPremier Wealth's Citius Pharmaceuticals position peaked at $16.9K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2026.

Based on BostonPremier Wealth's 13F filing for Q3 2026, filed 16 Oct 2026.